Sign in

NCT07410052Not yet recruiting

Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination

Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination (MENTOR)

Source: ClinicalTrials.gov · Last updated 13 Feb 2026

Brief summary (registry, in English)

This randomized, double-blind, placebo-controlled trial will evaluate whether 12 weeks of supplementation with the probiotic Lactobacillus rhamnosus GG combined with colon-delivered riboflavin will improve cognitive performance and brain physiology in older adults with memory complaints. The study will assess changes in cognitive outcomes together with neurophysiological markers to explore potential gut-brain axis mechanisms. Through its rigorous design, the trial will aim to determine whether targeted modulation of the intestinal environment can support brain function and cognitive health in aging.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
28 (estimated)
First submitted
7 Feb 2026
Start date
15 Apr 2026
Primary completion date
15 Jul 2027
Lead sponsor
Center for Health Sciences, Serbia
NCT number
NCT07410052

What you commit to

  • Study type: Interventional
  • Planned participants: 28
  • From 15 Apr 2026 to the primary completion date, 15 Jul 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of dietary supplement use four weeks before enrolment
  • Gut-altering medications two months before enrolment
  • Is currently using systemic steroids, proton pump inhibitors, H2 blocker, antacid
  • Has made any major dietary changes in the past 3 months prior to baseline

Other illness

  • Severe chronic disease and acute injuries
  • Organic gastrointestinal (GI) disorders
  • Bowel surgery or short bowel syndrome
  • History of drug and/or alcohol abuse at the time of enrolment
  • Has a currently active eating disorder
  • Has food allergies or other issues with foods

Other

  • Smoker or vaper

Who the study is looking for

  • Age \> 65 years
  • MoCA scores 18-25 points
  • BMI of 20.0 - 29.9 kg/m2 at screening
  • Stable body weight (≤ 5% change) over the past 3-months
  • Willing to avoid consuming gut microbiome-modulating dietary supplements within 4 weeks prior to the baseline visit
  • Subjects will abstain from vitamin B2-rich food intake as per pre-defined list
  • Maintain current level of physical activity
  • Be willing and able to comply with trial protocol

Age in the registry: 65 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.